KILANLSKNKRLVSEKVGQACCRPIAFDDDLSFLDDNLVYHILRKHSAK RCGCI (SEQ ID NO:12).

5. The human GDNF variant as claimed by Claim 2 wherein said variant is RGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCDAAETTYD KILANLSKNKRLVSEKVGQACCRPIAFDDDLSFLDDNLVYHILREHSAK ECGCI (SEQ ID NO:15).

6. An intermediate for preparing a Δ31-N-terminus truncated GDNF variant comprising an amino acid sequence selected from the group consisting of METDTLLLWVLLLWVPGSTGRGQRGKQRGCVLTAIHLNVTDLGLGYET KEELIFRYCSGSCDAAETTYDKILKNLSRNRRLVSEKVGQACCRPIAFDD DLSFLDDNLVYHILRKHSAKRCGCI (SEQ ID NO: 28); and MATGSRTSLLLAFGLLCLPWLQEGSARGQRGKQRGCVLTAIHLNVTDL GLGYETKEELIFRYCSGSCDAAETTYDKILKNLSRNRRLVSEKVGQACC RPIAFDDDLSFLDDNLVYHILRKHSAKRCGCI (SEQ ID NO: 35).

7. An intermediate as claimed by Claim 6 wherein the amino acid sequence is MATGSRTSLLLAFGLLCLPWLQEGSARGQRGKQRGCVLTAIHLNVTDL GLGYETKEELIFRYCSGSCDAAETTYDKILKNLSRNRRLVSEKVGQACC RPIAFDDDLSFLDDNLVYHILRKHSAKRCGCI (SEQ ID NO: 35).

8. A pharmaceutical composition comprising a human GDNF variant as claimed by any one of Claims 1 to 5 and one or more pharmaceutically acceptable diluents, carriers or excipients.

~~9. A method of treatment for Parkinson's disease comprising administering an effective amount of the composition of Claim 8 to a human patient in need thereof.~~

~~10.~~9. A human GDNF variant as claimed by any one of Claims 1 to 5 for use as a medicament.

~~11.~~10. A human GDNF variant as claimed by any one of Claims 1 to 5 for use in the treatment of Parkinson's disease.

~~12. A method for treating Parkinson's disease in a mammal, comprising the step of administering to the mammal a human GDNF variant as claimed by any one of Claims 1 through 5.~~

~~13.~~11. A human GDNF variant as claimed by any one of Claims 1 through 5 for use as a therapy.

~~14. A method of treatment of Parkinson's disease comprising adminstration of an effective amount of a human GDNF variant according to any one of claims 1 to 5 to a mammal in need thereof.~~